After spending ten years in academia, Gardner became interested in
research and development and entrepreneurship.[22] She mentored women interested in pursuit of the field of science.[27] She gained experience within the of companies seeking out
venture capital funding.[27] She developed several forms of slow released medication, including an adaptation for retention in the stomach.[28][29] Gardner has been involved with several start-ups in the
biotechnology and
pharmaceutical industries.[13] From 1996 to 1998 Gardner served as Vice President of Research and Head of the Technology Institute at the
Alza Corporation.[10] Gardner served as Director of the
biopharmaceutical company Revance Therapeutics from 2007 to 2018.[30] She is an adjunct partner at Essex Woodlands Health Ventures.[31] She founded several companies, including the Genomics Collaborative, SKOLAR and the CambriaTech Holding Co.[32] She was appointed to the Board Of Directors of Ventaira Pharmaceuticals in 2006.[32] Gardner serves on the Board of Fellows of the
Harvard Medical School.[33] She was appointed to the Board of Directors of CohBar, a clinical stage biotechnology company, in 2019.[5]
In 2002,
Elizabeth Holmes visited Gardner at
Stanford University.[27][7][34] Holmes proposed her idea for a
microfluidic device that could detect and treat infectious diseases.[27][7][34] Gardner was critical of the proposal, and told Holmes she did not think her invention would be successful.[35][36][37] She explained to Holmes that it is not possible to use antibiotics on such a small scale.[7][38][39] Holmes dropped out of Stanford a few months later, but Gardner followed the evolution of
Theranos.[38] Very briefly, both Gardner and Holmes served on the Harvard Medical School Board of Fellows after Holmes was given an invitation to join.[1] Gardner did not permit Holmes to visit the
Stanford campus and called for her to be sent to prison.[40][27] Holmes was ultimately found guilty of
criminal fraud, in the federal case, United States v. Elizabeth A. Holmes, et al. — which was brought by the United States against her and
Theranos former president and COO
Sunny Balwani.[7][1][6]
Gardner, Phyllis; Schulman, Howard (1989), "Response: Is Regulation of a Chloride Channel in Lymphocytes Affected in Cystic Fibrosis?", Science, 246 (4933): 1049–1050,
doi:
10.1126/science.246.4933.1049.b
Sudduth-Klinger, Julie; Schumann, Muhammad; Gardner, Phyllis; Payan, Donald (1992), "Functional and immunological responses of Jurkat lymphocytes transfected with the substance P receptor", Cellular and Molecular Neurobiology, 12 (5): 379–95,
doi:
10.1007/BF00711540,
PMID1281754
Wagner, John; Nepomuceno, Ilynn; Messner, Anna; Moran, Mary; Batson, Eric; Dimiceli, Sue; Brown, Byron; Desch, Julie; Norbash, Alexander; Conrad, Carol; Guggino, William; Flotte, Terence; Wine, Jeffrey; Carter, Barrie; Reynolds, Thomas; Moss, Richard; Gardner, Phyllis (2002), "A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies", Human Gene Therapy, 13 (11): 1349–59,
doi:
10.1089/104303402760128577,
PMID12162817
Sheridan, Colleen; Heist, E; Beals, Chan; Crabtree, Gerald; Gardner, Phyllis (2003), "Protein Kinase A Negatively Modulates the Nuclear Accumulation of NF-ATc1 by Priming for Subsequent Phosphorylation by Glycogen Synthase Kinase-3", The Journal of Biological Chemistry, 277 (50): 48664–76,
doi:10.1074/jbc.M207029200,
PMID12351631
Schrijver, Iris; Karnsakul, Wikrom; Limwongse, Chanin; Ramalingam, Sudha; Sankaran, Ramalingam; Gardner, Phyllis; Moss, Richard (2005), "Novel contributions to the Asian CFTR mutation spectrum: Genotype and phenotype in Thai patients with cystic fibrosis", American Journal of Medical Genetics, 133A (1): 103–5,
doi:
10.1002/ajmg.a.30472,
PMID15744829
Schrijver, Iris; Ramalingam, Sudha; Sankaran, Ramalingam; Swanson, Steve; Dunlop, Charles; Keiles, Steven; Moss, Richard; Oehlert, John; Gardner, Phyllis; Wassman, E; Kammesheidt, Anja (2005), "Diagnostic testing by CFTR gene mutation analysis in a large group hispanics: Novel mutations and assessment of a population-specific mutation spectrum", The Journal of Molecular Diagnostics, 7 (2): 289–99,
doi:
10.1016/S1525-1578(10)60557-0,
PMC1867528,
PMID15858154
Gardner, Phyllis; Oitmaa, Eneli; Messner, Anna; Hoefsloot, Lies; Schrijver, Iris (2006), "Simultaneous Multigene Mutation Detection in Patients With Sensorineural Hearing Loss Through a Novel Diagnostic Microarray: A New Approach for Newborn Screening Follow-up", Pediatrics, 118 (3): 985–94,
doi:
10.1542/peds.2005-2519,
PMID16950989
Naguib, Maggie; Schrijver, Iris; Gardner, Phyllis; Pique, Lynn; Doss, Samiha; Abu-Zekry, Mona; Aziz, Mona; Nasr, Samya (2007), "Cystic fibrosis detection in high-risk Egyptian children and CFTR mutation analysis", Journal of Cystic Fibrosis, 6 (2), European Cystic Fibrosis Society: 111–6,
doi:10.1016/j.jcf.2006.04.004,
PMID16837250
Naguib, Maggie; Schrijver, I.; Gardner, Phyllis; Piquet, L.; Doss, S.; Abu-Zekry, Mona; Aziz, M.; Nasré, S. (2006), "472 Incidence of Cystic Fibrosis in high-risk Egyptian children and CFTR mutation analysis", Journal of Cystic Fibrosis, 5: S103,
doi:
10.1016/S1569-1993(06)80396-6
Schrijver, Iris; Külm, Maigi; Gardner, Phyllis; Pergament, Eugene; Fiddler, Morris (2007), "Comprehensive Arrayed Primer Extension Array for the Detection of 59 Sequence Variants in 15 Conditions Prevalent Among the (Ashkenazi) Jewish Population", The Journal of Molecular Diagnostics, 9 (2): 228–36,
doi:
10.2353/jmoldx.2007.060100,
PMC1867437,
PMID17384215
Rodriguez-Paris, Juan; Ballay, Charles; Inserra, Michelle; Stidham, Katrina; Colen, Tahl; Roberson, Joseph; Gardner, Phyllis; Schrijver, Iris (2008), "Genetic Analysis of Presbycusis by Arrayed Primer Extension", Annals of Clinical and Laboratory Science, 38 (4): 352–60,
PMID18988928
Teek, Rita; Oitmaa, Eneli; Kruustük, Katrin; Zordania, Riina; Joost, Kairit; Raukas, Elve; Tõnisson, Neeme; Gardner, Phyllis; Schrijver, Iris; Kull, Mart; Ounap, Katrin (2008), "Splice variant IVS2-2A>G in the SLC26A5 (Prestin) gene in five Estonian families with hearing loss", International Journal of Pediatric Otorhinolaryngology, 73 (1): 103–7,
doi:
10.1016/j.ijporl.2008.10.003,
PMID19027966
Rodriguez-Paris, Juan; Pique, Lynn; Colen, Tahl; Roberson, Joseph; Gardner, Phyllis; Schrijver, Iris (2010), "Genotyping with a 198 Mutation Arrayed Primer Extension Array for Hereditary Hearing Loss: Assessment of Its Diagnostic Value for Medical Practice", PLOS One, 5 (7): e11804,
Bibcode:
2010PLoSO...511804R,
doi:10.1371/journal.pone.0011804,
PMC2909915,
PMID20668687
Traynis, Ilana; Bernstein, Jonathan; Gardner, Phyllis; Schrijver, Iris (2011), "Analysis of the Alternative Splicing of an FGFR2 Transcript Due to a Novel 5 ' Splice Site Mutation (1084+1G > A): Case Report", The Cleft Palate-Craniofacial Journal, 49 (1), American Cleft Palate-Craniofacial Association: 104–8,
doi:
10.1597/10-217,
PMID21524234
Academic conferences
Premack, B.A.; Gardner, Phyllis (1994), "Properties of Ca Currents Activated by T Cell Receptor Signaling", 5th International Conference on Mechanisms of Lymphocyte Activation and Immune Regulation, Advances in Experimental Medicine and Biology, vol. 365, Plenum Press, pp. 91–102,
doi:
10.1007/978-1-4899-0987-9_10,
ISBN978-1-4899-0989-3,
PMID7887318
Wagner, J A; Messner, A H; Moran, M L; Daifuku, R; Kouyama, K; Desch, J K; Manley, S; Norbash, A M; Conrad, C K; Friborg, S; Reynolds, T; Guggino, W B; Moss, R B; Carter, B J; Wine, J J; Flotte, T R; Gardner, Phyllis (1999), "Safety and biological efficacy of an adeno-associated virus vector cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus", 11th Annual North American Cystic Fibrosis Conference, vol. 109, no. 2, John Wiley & Sons Inc., pp. 266–74,
doi:
10.1097/00005537-199902000-00017,
PMID10890777
Gardner, Phyllis (2005), "Microfabricated silicon NanoPORE membranes provide continuous delivery of biopharmaceuticals", International Conference on MEMS, NANO and Smart Systems, vol. 179, IEEE, p. 179,
doi:
10.1109/ICMENS.2005.70,
ISBN0-7695-2398-6
^
abMurphy, Mary C. (2024), Cultures of Growth: How the New Science of Mindset Can Transform Individuals, Teams, and Organizations,
Simon & Schuster, pp. 164–166,
ISBN978-1982172749
^Dennin, Torsten (2023), "Chasing Unicorns: Elizabeth Holmes, Theranos, and the Disgrace of Silicon Valley", Games of Greed: Excess, Hubris, Fraud, and Theft on Main Street and Wall Street, River Grove Books, pp. 123–136,
ISBN978-1632996428
^Abbas, Ali (2023), Ethical Decision Quality: Building an Ethical Decision Culture, Ethics International Press Limited, pp. 51–53,
ISBN978-1804412213
After spending ten years in academia, Gardner became interested in
research and development and entrepreneurship.[22] She mentored women interested in pursuit of the field of science.[27] She gained experience within the of companies seeking out
venture capital funding.[27] She developed several forms of slow released medication, including an adaptation for retention in the stomach.[28][29] Gardner has been involved with several start-ups in the
biotechnology and
pharmaceutical industries.[13] From 1996 to 1998 Gardner served as Vice President of Research and Head of the Technology Institute at the
Alza Corporation.[10] Gardner served as Director of the
biopharmaceutical company Revance Therapeutics from 2007 to 2018.[30] She is an adjunct partner at Essex Woodlands Health Ventures.[31] She founded several companies, including the Genomics Collaborative, SKOLAR and the CambriaTech Holding Co.[32] She was appointed to the Board Of Directors of Ventaira Pharmaceuticals in 2006.[32] Gardner serves on the Board of Fellows of the
Harvard Medical School.[33] She was appointed to the Board of Directors of CohBar, a clinical stage biotechnology company, in 2019.[5]
In 2002,
Elizabeth Holmes visited Gardner at
Stanford University.[27][7][34] Holmes proposed her idea for a
microfluidic device that could detect and treat infectious diseases.[27][7][34] Gardner was critical of the proposal, and told Holmes she did not think her invention would be successful.[35][36][37] She explained to Holmes that it is not possible to use antibiotics on such a small scale.[7][38][39] Holmes dropped out of Stanford a few months later, but Gardner followed the evolution of
Theranos.[38] Very briefly, both Gardner and Holmes served on the Harvard Medical School Board of Fellows after Holmes was given an invitation to join.[1] Gardner did not permit Holmes to visit the
Stanford campus and called for her to be sent to prison.[40][27] Holmes was ultimately found guilty of
criminal fraud, in the federal case, United States v. Elizabeth A. Holmes, et al. — which was brought by the United States against her and
Theranos former president and COO
Sunny Balwani.[7][1][6]
Gardner, Phyllis; Schulman, Howard (1989), "Response: Is Regulation of a Chloride Channel in Lymphocytes Affected in Cystic Fibrosis?", Science, 246 (4933): 1049–1050,
doi:
10.1126/science.246.4933.1049.b
Sudduth-Klinger, Julie; Schumann, Muhammad; Gardner, Phyllis; Payan, Donald (1992), "Functional and immunological responses of Jurkat lymphocytes transfected with the substance P receptor", Cellular and Molecular Neurobiology, 12 (5): 379–95,
doi:
10.1007/BF00711540,
PMID1281754
Wagner, John; Nepomuceno, Ilynn; Messner, Anna; Moran, Mary; Batson, Eric; Dimiceli, Sue; Brown, Byron; Desch, Julie; Norbash, Alexander; Conrad, Carol; Guggino, William; Flotte, Terence; Wine, Jeffrey; Carter, Barrie; Reynolds, Thomas; Moss, Richard; Gardner, Phyllis (2002), "A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies", Human Gene Therapy, 13 (11): 1349–59,
doi:
10.1089/104303402760128577,
PMID12162817
Sheridan, Colleen; Heist, E; Beals, Chan; Crabtree, Gerald; Gardner, Phyllis (2003), "Protein Kinase A Negatively Modulates the Nuclear Accumulation of NF-ATc1 by Priming for Subsequent Phosphorylation by Glycogen Synthase Kinase-3", The Journal of Biological Chemistry, 277 (50): 48664–76,
doi:10.1074/jbc.M207029200,
PMID12351631
Schrijver, Iris; Karnsakul, Wikrom; Limwongse, Chanin; Ramalingam, Sudha; Sankaran, Ramalingam; Gardner, Phyllis; Moss, Richard (2005), "Novel contributions to the Asian CFTR mutation spectrum: Genotype and phenotype in Thai patients with cystic fibrosis", American Journal of Medical Genetics, 133A (1): 103–5,
doi:
10.1002/ajmg.a.30472,
PMID15744829
Schrijver, Iris; Ramalingam, Sudha; Sankaran, Ramalingam; Swanson, Steve; Dunlop, Charles; Keiles, Steven; Moss, Richard; Oehlert, John; Gardner, Phyllis; Wassman, E; Kammesheidt, Anja (2005), "Diagnostic testing by CFTR gene mutation analysis in a large group hispanics: Novel mutations and assessment of a population-specific mutation spectrum", The Journal of Molecular Diagnostics, 7 (2): 289–99,
doi:
10.1016/S1525-1578(10)60557-0,
PMC1867528,
PMID15858154
Gardner, Phyllis; Oitmaa, Eneli; Messner, Anna; Hoefsloot, Lies; Schrijver, Iris (2006), "Simultaneous Multigene Mutation Detection in Patients With Sensorineural Hearing Loss Through a Novel Diagnostic Microarray: A New Approach for Newborn Screening Follow-up", Pediatrics, 118 (3): 985–94,
doi:
10.1542/peds.2005-2519,
PMID16950989
Naguib, Maggie; Schrijver, Iris; Gardner, Phyllis; Pique, Lynn; Doss, Samiha; Abu-Zekry, Mona; Aziz, Mona; Nasr, Samya (2007), "Cystic fibrosis detection in high-risk Egyptian children and CFTR mutation analysis", Journal of Cystic Fibrosis, 6 (2), European Cystic Fibrosis Society: 111–6,
doi:10.1016/j.jcf.2006.04.004,
PMID16837250
Naguib, Maggie; Schrijver, I.; Gardner, Phyllis; Piquet, L.; Doss, S.; Abu-Zekry, Mona; Aziz, M.; Nasré, S. (2006), "472 Incidence of Cystic Fibrosis in high-risk Egyptian children and CFTR mutation analysis", Journal of Cystic Fibrosis, 5: S103,
doi:
10.1016/S1569-1993(06)80396-6
Schrijver, Iris; Külm, Maigi; Gardner, Phyllis; Pergament, Eugene; Fiddler, Morris (2007), "Comprehensive Arrayed Primer Extension Array for the Detection of 59 Sequence Variants in 15 Conditions Prevalent Among the (Ashkenazi) Jewish Population", The Journal of Molecular Diagnostics, 9 (2): 228–36,
doi:
10.2353/jmoldx.2007.060100,
PMC1867437,
PMID17384215
Rodriguez-Paris, Juan; Ballay, Charles; Inserra, Michelle; Stidham, Katrina; Colen, Tahl; Roberson, Joseph; Gardner, Phyllis; Schrijver, Iris (2008), "Genetic Analysis of Presbycusis by Arrayed Primer Extension", Annals of Clinical and Laboratory Science, 38 (4): 352–60,
PMID18988928
Teek, Rita; Oitmaa, Eneli; Kruustük, Katrin; Zordania, Riina; Joost, Kairit; Raukas, Elve; Tõnisson, Neeme; Gardner, Phyllis; Schrijver, Iris; Kull, Mart; Ounap, Katrin (2008), "Splice variant IVS2-2A>G in the SLC26A5 (Prestin) gene in five Estonian families with hearing loss", International Journal of Pediatric Otorhinolaryngology, 73 (1): 103–7,
doi:
10.1016/j.ijporl.2008.10.003,
PMID19027966
Rodriguez-Paris, Juan; Pique, Lynn; Colen, Tahl; Roberson, Joseph; Gardner, Phyllis; Schrijver, Iris (2010), "Genotyping with a 198 Mutation Arrayed Primer Extension Array for Hereditary Hearing Loss: Assessment of Its Diagnostic Value for Medical Practice", PLOS One, 5 (7): e11804,
Bibcode:
2010PLoSO...511804R,
doi:10.1371/journal.pone.0011804,
PMC2909915,
PMID20668687
Traynis, Ilana; Bernstein, Jonathan; Gardner, Phyllis; Schrijver, Iris (2011), "Analysis of the Alternative Splicing of an FGFR2 Transcript Due to a Novel 5 ' Splice Site Mutation (1084+1G > A): Case Report", The Cleft Palate-Craniofacial Journal, 49 (1), American Cleft Palate-Craniofacial Association: 104–8,
doi:
10.1597/10-217,
PMID21524234
Academic conferences
Premack, B.A.; Gardner, Phyllis (1994), "Properties of Ca Currents Activated by T Cell Receptor Signaling", 5th International Conference on Mechanisms of Lymphocyte Activation and Immune Regulation, Advances in Experimental Medicine and Biology, vol. 365, Plenum Press, pp. 91–102,
doi:
10.1007/978-1-4899-0987-9_10,
ISBN978-1-4899-0989-3,
PMID7887318
Wagner, J A; Messner, A H; Moran, M L; Daifuku, R; Kouyama, K; Desch, J K; Manley, S; Norbash, A M; Conrad, C K; Friborg, S; Reynolds, T; Guggino, W B; Moss, R B; Carter, B J; Wine, J J; Flotte, T R; Gardner, Phyllis (1999), "Safety and biological efficacy of an adeno-associated virus vector cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus", 11th Annual North American Cystic Fibrosis Conference, vol. 109, no. 2, John Wiley & Sons Inc., pp. 266–74,
doi:
10.1097/00005537-199902000-00017,
PMID10890777
Gardner, Phyllis (2005), "Microfabricated silicon NanoPORE membranes provide continuous delivery of biopharmaceuticals", International Conference on MEMS, NANO and Smart Systems, vol. 179, IEEE, p. 179,
doi:
10.1109/ICMENS.2005.70,
ISBN0-7695-2398-6
^
abMurphy, Mary C. (2024), Cultures of Growth: How the New Science of Mindset Can Transform Individuals, Teams, and Organizations,
Simon & Schuster, pp. 164–166,
ISBN978-1982172749
^Dennin, Torsten (2023), "Chasing Unicorns: Elizabeth Holmes, Theranos, and the Disgrace of Silicon Valley", Games of Greed: Excess, Hubris, Fraud, and Theft on Main Street and Wall Street, River Grove Books, pp. 123–136,
ISBN978-1632996428
^Abbas, Ali (2023), Ethical Decision Quality: Building an Ethical Decision Culture, Ethics International Press Limited, pp. 51–53,
ISBN978-1804412213